13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001622627
Total reported value
$269.2M
$269.2M
39 檔
40.3%
During the Q3 2025 filing period, Rosalind Advisors, Inc. (CIK: 0001622627) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $269.2M across 39 reported positions.
In Q3 2025, Rosalind Advisors, Inc. displayed an active expansion posture, initiating 18 new positions and adding to 12 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DCTH | Delcath Systems Inc | Stock-Other | 11.55% | +3.13% | — | |
| 2 | CYTK | Cytokinetics Inc | Stock-Healthcare | 7.69% | — | — | |
| 3 | FENC | Fennec Pharmaceuticals Inc | Stock-Other | 6.80% | +5.54% | +1.52% | |
| 4 | VSTM | Verastem Inc | Stock-Other | 5.96% | +1.11% | -5.58% | |
| 5 | RZLT | Rezolute Inc | Stock-Other | 5.94% | — | +3.79% | |
| 6 | XERS | Xeris Biopharma Holdings Inc | Stock-Other | 5.12% | +1.03% | -16.69% | |
| 7 | SVRA | Savara Inc | Stock-Other | 5.00% | +0.24% | +50.66% | |
| 8 | ✓ | Mediwound LTD | Stock-Other | 4.72% | -0.76% | +84.02% | |
| 9 | VRDN | Viridian Therapeutics Inc | Stock-Other | 4.53% | -1.97% | EXIT | |
| 10 | CGON | Cg Oncology Inc | Stock-Other | 4.23% | -2.72% | EXIT | |
| 11 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 3.73% | — | — | |
| 12 | IDYA | Ideaya Biosciences Inc | Stock-Other | 3.33% | — | -31.52% | |
| 13 | NSPR | Inspiremd Inc | Stock-Other | 3.29% | -1.54% | +70.62% | |
| 14 | EYPT | Eyepoint Inc | Stock-Other | 3.24% | -0.12% | — | |
| 15 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 3.09% | — | +78.57% | |
| 16 | HELP | Cybin Inc | Stock-Other | 3.09% | +1.85% | +84.98% | |
| 17 | GUTS | Fractyl Health Inc | Stock-Other | 2.78% | — | — | |
| 18 | QURE | uniQure N.V. | Stock-Other | 2.55% | — | — | |
| 19 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 1.85% | +0.25% | — | |
| 20 | OCUL | Ocular Therapeutix Inc | Stock-Other | 1.64% | — | -67.18% | |
| 21 | ✓ | Atyr Pharma Inc | Stock-Other | 1.56% | — | +604.13% | |
| 22 | TLPH | Talphera Inc | Stock-Other | 1.37% | +0.97% | +118.86% | |
| 23 | PROF | Profound Medical CORP | Stock-Other | 1.18% | -0.11% | — | |
| 24 | MYO | Myomo Inc | Stock-Other | 1.18% | +0.37% | +5.42% | |
| 25 | ✓ | Polypid LTD | Stock-Other | 1.07% | -0.32% | -5.82% | |
| 26 | ✓ | Invesco QQQ Tr Put Option 06/2 | Stock-Other | 0.54% | -0.42% | EXIT | |
| 27 | BFRI | Biofrontera Inc | Stock-Other | 0.39% | +0.07% | +16.83% | |
| 28 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.39% | — | — | |
| 29 | ✓ | Spdr Series Trust | Stock-Other | 0.33% | +0.01% | NEW | |
| 30 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.32% | — | -66.67% | |
| 31 | ✓ | Verastem Inc | Stock-Other | 0.31% | — | — | |
| 32 | KURA | Kura Oncology Inc | Stock-Other | 0.31% | +0.08% | — | |
| 33 | ATYR | Atyr Pharma Inc | Stock-Other | 0.26% | — | — | |
| 34 | ✓ | Spdr S&P 500 Etf Tr Put Option | ETF-Large Cap & Growth | 0.25% | -0.39% | EXIT | |
| 35 | ✓ | Rezolute Inc | Stock-Other | 0.19% | — | — | |
| 36 | ✓ | Ideaya Biosciences Inc | Stock-Other | 0.08% | — | +79.50% | |
| 37 | ✓ | Replimune Group Inc | Stock-Other | 0.06% | -1.10% | EXIT | |
| 38 | ✓ | Ishares Tr | Stock-Other | 0.01% | +0.04% | NEW | |
| 39 | ✓ | Scholar Rock Hldg CORP | Stock-Other | — | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BRD1EUR | Mind Medicine Mindmed Inc | +1.8% | +78.57% | Add |
| 2 | FENC | Fennec Pharmaceuticals Inc | +1.4% | +1.52% | Add |
| 3 | SVRA | Savara Inc | +1.3% | +50.66% | Add |
| 4 | TLPH | Talphera Inc | +0.9% | +118.86% | Add |
| 5 | ✓ | Mediwound LTD | +0.8% | +84.02% | Add |
| 6 | VRNA | Verona Pharma PLC - Adr | +0.6% | — | Unchanged |
| 7 | VRDN | Viridian Therapeutics Inc | +0.5% | -14.29% | Add |
| 8 | HELP | Cybin Inc | +0.5% | +84.98% | Add |
| 9 | ✓ | Invesco QQQ Tr Put Option 06/2 | +0.4% | — | Add |
| 10 | NSPR | Inspiremd Inc | +0.2% | +70.62% | Add |
| 11 | BFRI | Biofrontera Inc | +0.1% | +16.83% | Add |
| 12 | KURA | Kura Oncology Inc | 0% | — | Unchanged |
| 13 | ✓ | Polypid LTD | -0.3% | -5.82% | Trim |
| 14 | PROF | Profound Medical CORP | -0.8% | — | Unchanged |
| 15 | TRVI | Trevi Therapeutics Inc | -1.6% | -66.67% | Trim |
| 16 | XERS | Xeris Biopharma Holdings Inc | -1.7% | -16.69% | Trim |
| 17 | VSTM | Verastem Inc | -1.9% | -5.58% | Trim |
| 18 | IDYA | Ideaya Biosciences Inc | -2.3% | -31.52% | Trim |
| 19 | OCUL | Ocular Therapeutix Inc | -2.7% | -67.18% | Trim |
| 20 | DCTH | Delcath Systems Inc | -2.8% | — | Add |
| 21 | MYO | Myomo Inc | -5.2% | +5.42% | Add |
| 22 | CYTK | Cytokinetics Inc | — | NEW | New buy |
| 23 | RZLT | Rezolute Inc | — | NEW | New buy |
| 24 | CGON | Cg Oncology Inc | — | NEW | New buy |
| 25 | URGN | UroGen Pharma Ltd. | — | EXIT | Sold out |
| 26 | EYPT | Eyepoint Inc | — | NEW | New buy |
| 27 | ABEO | Abeona Therapeutics Inc | — | EXIT | Sold out |
| 28 | REPL | Replimune Group Inc | — | EXIT | Sold out |
| 29 | GUTS | Fractyl Health Inc | — | NEW | New buy |
| 30 | ATYR | Atyr Pharma Inc | — | NEW | New buy |
| 31 | QURE | uniQure N.V. | — | NEW | New buy |
| 32 | XFOR | X4 Pharmaceuticals Inc | — | NEW | New buy |
| 33 | ✓ | Atyr Pharma Inc | — | NEW | New buy |
| 34 | NUVB | Nuvation Bio Inc | — | EXIT | Sold out |
| 35 | PHVS | Pharvaris N.V. | — | EXIT | Sold out |
| 36 | 4XC1 | Kalvista Pharmaceuticals Inc | — | EXIT | Sold out |
| 37 | CMPS | Compass Pathways PLC | — | EXIT | Sold out |
| 38 | OPTNUSD | Optinose Inc | — | EXIT | Sold out |
| 39 | COGT | Cogent Biosciences Inc | — | EXIT | Sold out |
| 40 | CATBUSD | Astria Therapeutics Inc | — | NEW | New buy |
| 41 | ✓ | Spdr Series Trust | — | NEW | New buy |
| 42 | ✓ | Verastem Inc | — | NEW | New buy |
| 43 | KPRX | Kiora Pharmaceuticals Inc | — | EXIT | Sold out |
| 44 | ✓ | Spdr S&P 500 Etf Tr Put Option | — | NEW | New buy |
| 45 | ✓ | Rezolute Inc | — | NEW | New buy |
| 46 | ACOG | Alpha Cognition Inc | — | EXIT | Sold out |
| 47 | ✓ | Ideaya Biosciences Inc | — | NEW | New buy |
| 48 | ✓ | Replimune Group Inc | — | NEW | New buy |
| 49 | ✓ | Lexicon Pharmaceuticals Inc | — | EXIT | Sold out |
| 50 | ✓ | Ishares Tr | — | NEW | New buy |
According to official SEC Form 13F filings, Rosalind Advisors, Inc. reported a total U.S. public equity portfolio value of $269.2M across 39 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including DCTH, CYTK, FENC) accounted for 40.3% of total reported equity market value during Q3 2025.
Top New Position Initiated
CYTK
市值: $22.0M
Top Position Liquidated / Trimmed
URGN
前期市值: $10.5M
During Q3 2025, Rosalind Advisors, Inc.'s top holdings by market value included DCTH (11.6%)、CYTK (7.7%)、FENC (6.8%). The largest single position, DCTH, represented 11.6% of total portfolio value.
In Q3 2025, Rosalind Advisors, Inc. made 49 total portfolio adjustments, initiating 18 new buys, adding to 12 positions, trimming 6 holdings, and fully liquidating 13 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.